TABLE 3.
Regulatory factors of GPX4.
| Regulatory factor | The regulation of GPX4 | Cancer |
|---|---|---|
| RSL3 | GPX4 Inactivation | Colorectal Cancer (Sui et al., 2018) |
| DMOCPTL | induced GPX4 ubiquitination | triple negative breast cancer (Ding et al., 2021) |
| FZD7 | Indirectly upregulate GPX4 | Ovarian Cancer (Wang R. et al., 2021) |
| Fin56 | promote GPX4 protein degradation | bladder cancer (Sun Y. et al., 2021) |
| RB | GPX4 inactivation | colorectal cancer (Shen et al., 2021) |
| KLF2 | transcriptional repression of GPX4 | clear cell renal cell carcinoma (Lu Y. et al., 2021) |
| SFRS9 | upregulate | Colorectal Cancer (Wang Y. et al., 2021) |
| circKIF4A | Indirectly upregulate GPX4 | papillary thyroid cancer (Chen W. et al., 2021) |
| EBV | Indirectly upregulate GPX4 | nasopharyngeal carcinoma (Yuan et al., 2022) |
| CREB | upregulate | lung adenocarcinoma (Wang Z. et al., 2021) |
| DHA | GPX4 Inactivation | glioblastoma (Yi et al., 2020) |
| GSTZ1 | Indirectly downregulate GPX4 | hepatocellular carcinoma (Wang Z. et al., 2021) |
| Metformin | Indirectly downregulate GPX4 | breast cancer (Hou et al., 2021) |
| Apatinib | Indirectly downregulate GPX4 | gastric cancer (Zhao et al., 2021) |
| Ketamine | Indirectly downregulate GPX4 | Liver Cancer (He et al., 2021) |
RSL3, ferroptosis inducer; DMOCPTL, a derivative of natural product parthenolide; FZD7, the Wnt receptor Frizzled-7; Fin56, ferroptosis inducer; RB, Resibufogenin; KLF2, Kruppel like factor 2; SFRS9, Serine and arginine rich splicing factor 9; circKIF4A, Circular RNA; EBV, Epstein-Barr virus; CREB, cAMP, response element-binding protein; DHA, Dihydroartemisinin; GSTZ1, Glutathione S-transferase zeta 1.